stockportfolio.pro
Tempus AI, Inc. (TEM)
Healthcare · Health Information Services · NasdaqGS
Tempus AI, Inc. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $320.67M | $531.82M | $693.40M | $1.27B |
| Gross profit | $130.19M | $286.18M | $381.11M | $797.90M |
| Net income | $-289.81M | $-214.12M | $-705.81M | $-245.03M |
| Net margin | -90.4% | -40.3% | -101.8% | -19.3% |
Source: Tempus AI, Inc. SEC filings (10-K).
Explore 4 years of Tempus AI, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track TEM in your portfolio →
Tempus AI, Inc. financial history by metric
About Tempus AI, Inc.
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Tempus AI, Inc. — frequently asked questions
What is Tempus AI, Inc.'s revenue?
Tempus AI, Inc. (TEM) reported revenue of $1.27B for fiscal year 2025, up 83.4% from the prior year, according to its SEC filings.
Is Tempus AI, Inc. profitable?
No — TEM reported a net loss of $-245.03M in fiscal 2025.
What is TEM's P/E ratio?
Tempus AI, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Tempus AI, Inc. growing?
TEM's revenue grew at roughly 58.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Tempus AI, Inc. have?
As of fiscal year 2025, TEM carried roughly $1.24B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Tempus AI, Inc.'s gross margin?
TEM's gross margin was 62.7% in fiscal 2025 — gross profit of $797.90M on revenue of $1.27B.
What is Tempus AI, Inc.'s market cap?
Tempus AI, Inc. (TEM) has a market capitalization of about $8.68B, based on the latest data in our nightly-refreshed cache.
When does Tempus AI, Inc.'s fiscal year end?
TEM's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Tempus AI, Inc.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.